MRVI logo

MARAVAI LIFESCIENCES HLDGS-A

MRVINASDAQ
πŸ† #1947 by market capEarnings Nov 4 Β· PostUS Equity
$606.29β–² $6.91 (+1.14%)
Simulated price
πŸ””
Track MRVI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.11B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-28.3%
Declining
πŸ“ŠGross Margin
34.6%
Moderate
πŸ’΅FCF Margin
-16.8%
Thin
βš–οΈP/S Ratio
10.1x
Elevated
Otter Score
60
Fair
No chart data available for MRVI.

Trading Snapshot

Day Range
$600.59 – $615.11
52-Week Range
$2.55 – $9.42
Volume
$2.51B
Avg Volume
$2.37B
Shares Outstanding
276.2M
Next Earnings
Oct 24, 2026

Fundamentals Snapshot

Annual Revenue
$186M
Last Q Revenue
$51M
P/E Ratio
-14.2
P/S Ratio
10.1x
EPS (TTM)
$-0.52
Dividend Yield
0.00%
Dilution (1yr)
+3.8%

Why Investors Own MRVI

  • βœ“High-growth profile β€” revenue up +56.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 58% gross margin and 25% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MRVI logo

MARAVAI LIFESCIENCES HLDGS-A

MRVI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$186Mβ–Ό βˆ’28.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
18.0%β–Ό βˆ’57.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$7Mβ–Ό βˆ’97.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$71Mβ–² +218.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
145.1Mβ–² +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$181Mβ–² +$236M YoY
StockOtter Β· stockotter.space

About MARAVAI LIFESCIENCES HLDGS-A

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Ratings

β“˜
Consensus
Buy
15 analysts
Strong Buy4
Buy6
Hold5
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates